Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual MeetingPivotal Phase 3…
December 6, 2025